EY Health Sciences & Wellness podcast series: Recent Episodes
EY
The EY Health Sciences and Wellness Experience podcast explores the age of “Health Experience.” All who use and touch the heath care value chain will soon demand a service that provides a more personalized and enhanced outcome. Join us and our guests, as we expand the traditional definitions of innovation to meet ever growing needs and expectations.
In this episode of the EY Health Sciences and Wellness Experience podcast, host Patrick T. O’Sullivan discusses how AI is currently being used to support pharmaceutical manufacturing and supply chain.
In this episode of the EY Health Sciences and Wellness Experience Podcast, Aloha McBride and her guests explore how organizations can reduce climate impact, increase efficiencies and unburden the system.
The speakers talk about the EY report Pharma supply chains of the future and discuss the impact of global events and how a new supply chain model can emerge.
Until recently, the pharma industry has been on the straight path to globalization with integrated supply chains that crossed national borders. A series of geopolitical upheavals though, from the COVID-19 pandemic, to the crisis in Ukraine, caused the industry to re-examine its priorities.
The COVID-19 pandemic and global political tensions highlighted the downsides of a highly integrated supply chain with global dependencies. Politicians started seeking greater guarantees of national and regional supply, rebalancing supply chains to national security and interests.
The discussion then moves to the response of the pharma industry in incorporating regionalization. A hybrid model is emerging that combines globalized thinking with greater self-sufficiency. The key is end-to-end visibility so that companies have a clear line of sight of their supply chain, enabling manufacturing to continue, even in the face of short-term crises, geopolitical tensions, or cyberattacks.
Two positives that emerged from the COVID-19 pandemic were greater collaboration between pharma companies, demonstrated by the vaccine development, and greater dialogue with policy makers. The way forward is the development of a partnership between pharma companies, policy makers, and regulatory bodies to build a new, resilient supply chain model.
Key takeaways: * Global tensions and crises have put pressure on pharma companies to re-examine their supply chains. * The emerging model is a hybrid one that combines globalization with regionalization. * End-to-end visibility is essential, not just with suppliers but with suppliers of suppliers. * The supply chain of the future will involve public/private partnerships and greater collaboration between stakeholders.
For your convenience, full text transcript of this podcast is also available. Read the transcript.
In this episode, Barend van Bergen, EY Global Long-term Value Methodology Leader and Sonja Haut, Head of Impact Valuation for Novartis discuss how companies are measuring their ESG impact.
In this episode of the EY Health Sciences and Wellness Experience podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, talks with Nancy Flores, Executive Vice President & Chief Information and Technology Officer for McKesson Corporation, about the unique complexities of healthcare – a sector with new entrants, new regulations, consolidation, pricing pressures, and an ageing population that needs ever more healthcare. But alongside the complexities, there are opportunities to disrupt.
In this episode of the EY Health Sciences and Wellness Experience podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, speaks with Trecilla Lobo, SVP, People, BenevolentAI, Rabia Khan, Founder/CEO, Ladder Therapeutics, and Samin Saeed, UK Chief Scientific Officer and Medical Director, Novartis, as they discuss their own unique career journeys within the health sciences and wellness industry. They also share with us those critical lessons they have learned from their mentors and supporters along the way.
In this episode of the EY Health Sciences and Wellness Experience Podcast, Pamela Spence, EY Global Health Sciences and Wellness Leader, Jackie Hunter, Board Director of Benevolent AI and Ridwaan Jhetam, VP Global Medical for Hematology, BMS, discuss the important of data and how it can help redesign the health experience. In this wide-ranging discussion, the expert panel approach these issues from their different perspectives. Whether you’re a doctor or researcher, a programmer or a CIO, whether you work in the field or you’re just looking in from outside, you’ll find this an insightful and timely listen.
There are 2,600 cell and gene therapy clinical trials taking place this year. In the US alone, this could translate up to 20 new therapy approvals in 2022, which presents a clear opportunity to make more life-saving therapies available to a greater number of individuals. In this podcast, Adlai Goldberg, Global Digital, Social and Commercial Innovation Life Sciences Leader for EY, talks to Tamie Joeckel – ICON’s Cell and Gene Therapy Global Business Lead, as they discuss what makes an increase in the volume of trials and an acceleration of the clinical trial process significant.
In this Pointellis episode, Adlai Goldberg and two prominent chief medical officers explore and frame the health equity challenges the world is facing today.
Addressing health care inequality is a global challenge. For Dr. Yele Aluko, EY Chief Medical Officer, and Dr. David Rhew, Microsoft Chief Medical Officer, finding opportunities to provide health equity is a shared passion. Both are experienced physicians, and in this podcast, we discuss why disparities exist, the root causes and unbiased digital solutions.
Health care disparity doesn’t begin at the time of diagnosis and treatment – it goes back further to clinical trials and the fact that low enrolment rates of minorities would generate results that were not reflective of the populations.
And while COVID-19 has both given rise to a groundswell of societal demand for equal treatment for all people, the pandemic has also highlighted the health disparities across populations.
The way forward requires strategic insight from the health care value chain. Using data and analytics to not only identify care gaps – but to then develop the tactics and solutions that will close them.
Microsoft is building technologies that can be used by millions to make things easier, with usability a key factor. Barriers such as lack of broadband, or physical disabilities such as poor vision and hearing, must be overcome.
Dr. Aluko and Dr. Rhew see health equity is an important mission, because achieving it means everyone has a better chance of fulfilling their life’s potential.
In this first episode of our EY Health Sciences and Wellness Experience podcast series, we explore the emerging and much needed age of “Health Experience.”
The Health Sciences and Wellness industry has never been as “front and center” in our lives as it has been in this last year. As all of us, worldwide, ride the various waves of the pandemic, our Health Sciences and Wellness industry has taken the lead in giving care to those who have needed it most. We have also seen a monumental collaborative R&D effort – at a scale never witnessed before – which has resulted in the creation and delivery of multiple approved vaccines to combat the virus.
Companies have an opportunity to seize this inflexion point, because the reality (as we have seen with other industries) is that products or services alone, no matter how strong technically will not be enough in future.